secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2023-11-03T23:59:59+00:00
Accession:  0001628280-23-036563
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Therapeutics Q3 net loss $11.3M; secures $30M from Ligand for soticlestat royalty interest
--------------------------------------------------------------------------------

- Received $30M from Ligand for 13% interest in soticlestat future royalties/milestones; cash runway extended into 2026.
- Cash and equivalents $87.1M as of Sep 30, 2023, excluding the $30M received in Oct.
- Net loss $11.3M ($0.16 per share) vs $12.0M ($0.17) in Q3 2022.
- Takeda anticipates regulatory filings for soticlestat in fiscal year 2024; two Phase 3 trials on track.
- OV329 expanding to IV formulation; IND expected H2 2024. OV350 (KCC2) IND also expected H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000162828023036563/0001628280-23-036563-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000162828023036563/ovid-20231103.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-036563

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer